Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...
Fri, April 3, 2026 at 2:17 PM UTC The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion ...
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...
Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.
Following the sale, iShares Biotechnology ETF is comprised 2.67% of DAFNA Capital’s 13F reportable assets under management. Top five holdings after the filing: NASDAQ:RVMD: $48.15 million (11.3% of ...
The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...
From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.
This article was originally published on ETFTrends.com. ETFs offering biotech exposure are rallying on Monday, lifted by a significant M&A announcement in the industry. The healthcare sector is up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results